Krystal Biotech (NASDAQ:KRYS) Receives “Neutral” Rating from Citigroup

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “neutral” rating restated by stock analysts at Citigroup in a report released on Tuesday, Marketbeat reports. They presently have a $166.00 price objective on the stock, down from their prior price objective of $176.00. Citigroup’s price target points to a potential upside of 21.12% from the stock’s current price.

A number of other brokerages have also commented on KRYS. Chardan Capital reissued a “buy” rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday. Bank of America dropped their price objective on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. HC Wainwright reiterated a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Friday, July 25th. Finally, Guggenheim dropped their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $210.22.

Krystal Biotech Stock Down 0.2%

NASDAQ:KRYS traded down $0.29 on Tuesday, hitting $137.06. The stock had a trading volume of 134,780 shares, compared to its average volume of 332,482. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $207.84. The business’s fifty day moving average is $141.24 and its 200 day moving average is $155.67. The company has a market cap of $3.96 billion, a PE ratio of 27.73 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. Equities analysts predict that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the transaction, the insider owned 1,508,056 shares in the company, valued at $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 49,800 shares of company stock worth $7,487,943 over the last quarter. 13.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently bought and sold shares of the business. Brooklyn Investment Group boosted its stake in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after purchasing an additional 105 shares during the period. Hantz Financial Services Inc. increased its holdings in Krystal Biotech by 8,950.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after acquiring an additional 179 shares during the period. Twin Tree Management LP bought a new stake in Krystal Biotech during the 1st quarter worth approximately $29,000. Fifth Third Bancorp lifted its stake in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after purchasing an additional 105 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its position in shares of Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after purchasing an additional 166 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).